Seeking Alpha
22 Nov 2026, 01:56 UTC · 2h ago
Edgewise Therapeutics: Breaking Out Of The Echo Chamber
Impact · against what's priced in
The initiation of EWTX suggests significant valuation upside based on combined asset values of $5.4 billion and a cash runway extending to 2032. While the clinical differentiation of EDG-7500 is noted, the primary catalyst is the analyst's specific valuation model implying a 40% premium over current levels.
- EWTX+0.30
No priced-in read yet
- In context
The analyst values the asset pipeline at $5.4 billion and notes a $1.74 billion cash position, supporting a target price of $59 against a current price of $42.
Read from the article alone





